Eli Lilly Alzheimer’s drug fails to prevent disease in trial
One of the biggest ever trials in Alzheimer’s has failed in a setback for researchers while also throwing doubt on the amyloid theory.
By Robert Langreth, bloomberg
An experimental Eli Lilly & Co. drug failed to prevent cognitive decline in people at risk for Alzheimer’s disease in a closely watched drug trial backed by the company and the US government.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Eli Lilly to lower insulin prices by 70% in US
For subscribers
